T1	Participants 97 205	patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors:
T2	Participants 428 540	patients with rheumatoid arthritis (RA) who had an inadequate response to tumor necrosis factor (TNF) inhibitors
T3	Participants 1243 1255	480 patients